Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | USP1 | O94782 | 7/20 | 0.38 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153505 | 0.81 | IDO1 (0.46) | GRM4TRPA1HDAC6PIK3CDNPC1 | |
| SCHEMBL10094325 | 0.75 | TRPA1 (0.61) | TRPA1ALOX5APFEN1NPC1 | |
| SCHEMBL29863719 | 0.74 | PIP4K2C (0.48) | TRPA1USP1PIP4K2CWDR48 | |
| SCHEMBL12749949 | 0.72 | PAK3 (0.41) | GRM4HDAC6LRRK2MAPT | |
| SCHEMBL15563635 | 0.71 | TRPA1 (0.47) | TRPA1ALOX5APFEN1PIP4K2CLRRK2 | |
| SCHEMBL29018615 | 0.70 | HDAC6 (0.41) | GRM4TRPA1HDAC6PIK3CDNPC1 | |
| SCHEMBL30354459 | 0.70 | HDAC6 (0.41) | GRM4TRPA1HDAC6PIK3CDNPC1 | |
| SCHEMBL1762547 | 0.70 | GRM4 (0.42) | GRM4HDAC6PIK3CDNPC1MAPT | |
| SCHEMBL21468927 | 0.68 | PIK3CD (0.45) | GRM4HDAC6PIK3CDLRRK2MAPT | |
| SCHEMBL15034376 | 0.68 | USP1 (0.45) | TRPA1ALOX5APFEN1USP1TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GRM4 2092/4885TRPA1 4597/4885ALOX5AP 4805/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GRM4 2092/4885TRPA1 4597/4885ALOX5AP 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.